Patient Data Collective (PDC) for Rare Diseases: Accelerating Drug Discovery

Subject: GS 3: Science and Technology

Context: A Patient Data Collective (PDC) has been proposed as a cooperative model to pool rare-disease patient data and accelerate drug discovery and treatment development.

UPSC Online Coaching

Why Patient Data Matters in Rare Diseases?

• Limited Patient Pool: Rare diseases affect relatively few people, making it difficult to recruit adequate participants for conventional clinical trials.
• Difficulty in Control Groups: Small patient populations may make conventional treatment-versus-control trial designs impractical.
• Disease Understanding: Long-term patient data helps researchers understand disease progression, biomarkers and treatment outcomes.
• Better Clinical Trials: Patient registries and natural-history studies can provide real-world evidence and help identify appropriate participants and clinical endpoints.
• Faster Drug Development: Comprehensive datasets can reduce uncertainty, improve trial design and increase the probability of regulatory approval.

About Rare Diseases

• A rare disease is a health condition affecting a very small proportion of the population, often having a genetic basis and causing significant health challenges.
  • World Health Organization (WHO) traditionally characterizes a rare disease as a debilitating, lifelong condition with a prevalence of 1 or fewer affected persons per 1,000 population (or roughly 0.65 to 1 per 1,000)
• Examples: cystic fibrosis, Huntington’s disease, ALS and acromegaly.
• Current Status: Over 7,000 rare diseases are identified globally, while many remain difficult to diagnose and lack effective approved treatments.

About Patient Data Collective (PDC)

• The PDC is a proposed patient-centric cooperative framework that would hold and manage patients’ medical data on their behalf for research and drug development.
  • It draws inspiration from the Amul cooperative model, where collective resources are managed for the benefit of participating members.
• Developed by: The proposal has been advanced by Alok Bhattacharya and Gayatri Saberwal as a potential model for rare-disease research in India.
  • It could work with patient advocacy groups, hospitals, clinicians, Centres of Excellence for Rare Diseases and digital health repositories.
• Key Features
  • Centralised Patient Data: The PDC would aggregate medical records, genetic reports, clinical notes and patient-reported information into a secure repository.
  • Consent-Based Data Governance: Patients would retain an important role in determining how their data are collected, stored, analysed and shared, with appropriate ethical and legal safeguards.
  • AI-Enabled Analytics: Generative AI and data analytics could identify disease patterns, support diagnosis and generate clinically relevant insights from large datasets.
• Potential Applications
  • Rare-Disease Drug Development: Comprehensive patient datasets can help researchers identify biomarkers, understand disease progression and design more effective clinical trials.
  • Natural-History Studies: Longitudinal patient data can document disease progression and provide real-world evidence or external controls where conventional control groups are difficult because of small patient populations.
  • Accelerating Clinical Research: PDC-generated datasets could help identify suitable trial participants, define meaningful clinical endpoints and enable virtual or synthetic control groups, potentially reducing the cost and duration of orphan-drug development.

Click to Explore UPSC Offline Coaching

The ICMR has already established a rare-disease registry, based on data from specialised hospitals; a PDC could expand such efforts through a broader, inclusive and patient-centric framework.

Check Out UPSC CSE Books

Visit PW Store